Top Markets
#1 Akedo Akedo +59.31%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +50.07%
#4 Velvet Velvet +43.76%
#5 Black Phoenix Black Phoenix +34.55%
#6 τemplar τemplar +26.67%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +18.66%
#8 Bitway Bitway +18.26%
#9 Perle Perle +16.48%
#10 Cap Cap +16.47%
Coin of the day
Akedo Akedo
設定
言語
日本
通貨
USD
テーマ
CohBar, Inc. CohBar, Inc.

CohBar, Inc.

CWBR
株式のランク #38304
CohBar Inc. is a clinical-stage biotechnology company dedicated to the... CohBar Inc. is a clinical-stage biotechnology company dedicated to the discovery and advancement of therapies that leverage mitochondrial biology, known as mitochondria-based therapeutics (MBTs). Their primary objective is to combat chronic conditions and diseases associated with aging. These MBTs are being developed to address a broad spectrum of medical challenges, including non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis (IPF), type 2 diabetes, acute respiratory distress syndrome (ARDS), various cancers, and cardiovascular disorders like Alzheimer's disease. Their flagship clinical asset is CB4211, an innovative, optimized analogue of the MOTS-c mitochondrial-derived peptide. This candidate is currently undergoing Phase Ib evaluation as part of a larger Phase Ia/Ib clinical trial, specifically targeting non-alcoholic steatohepatitis (NASH) and obesity. Beyond their clinical work, CohBar's preclinical portfolio features CB5138 analogs aimed at fibrotic conditions, as well as CB5064 analogs being explored for their potential in treating ARDS linked to COVID-19. Established in 2007, CohBar, Inc. maintains its corporate headquarters in Menlo Park, California.
株価
$0.41
最終同期: 2025-01-23
時価総額
$1.08M
変化（1日）
0.00%
変化（1年）
0.00%
国
US
取引 CohBar, Inc. (CWBR)

カテゴリー

Healthcare
CohBar, Inc.（CWBR）のP/B比率
August 2026 時点のP/B比率 TTM: 0.08
CohBar, Inc. の最新の財務報告および株価によると、現在のP/B比率（TTM）は 0.08 です。2021 年末時点でのP/B比率は 0.91 でした。
CohBar, Inc. の P/B 比率の履歴（2011 ～ 2026）
各年末時点のP/B比率
年 P/B比率 変化
2026 (TTM) 0.08 -75.78%
2022 0.32 -64.70%
2021 0.91 -74.27%
2020 3.54 -57.97%
2019 8.42 17.87%
2018 7.14 -70.78%
2017 24.44 213.13%
2016 7.81 115.36%
2015 3.62 -84.35%
2014 23.15 -103.81%
2013 -607.96 -3,077.68%
2012 20.42 0.00%
2011 0.00 0.00%
同業他社のP/B比率
企業 P/B比率 P/B比率の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 7,979.10%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 8,091.35%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 4,589.03%
BE